Alnylam Q4 2022 product revenue $262M (+35% YoY); guides 2023 revenue $1.2-1.285B

ALNYLAM PHARMACEUTICALS, INC.

2022-FY EPS reported -$9.30 revenue$1,037,418,000

Q4 2022 net product revenue $262M; full year $894M (+35% YoY). GAAP net loss $1.13B for 2022 vs $853M in 2021.
ONPATTRO Q4 rev $122M, AMVUTTRA $69M; total TTR rev $651M for 2022 (+37% YoY).
sNDA for ONPATTRO in ATTR cardiomyopathy accepted by FDA; PDUFA date Oct 8, 2023; advisory committee planned.
2023 guidance: combined net product revenue $1.2B-$1.285B; collaboration and royalty revenue also guided.
Cash $2.19B at year-end; appointed Carolyn Bertozzi to board; Amy Schulman becomes Chair.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported the year ending December 31, 2023 results: revenue $1,200 Million to $1,285 Million. Guidance initiated.

Period: the year ending December 31, 2023
Revenue: $1,200 Million to $1,285 Million
Guidance: initiated
Result: guidance update

Exact text from the filing

Provides 2023 Combined Net Product Revenue Guidance of $1,200 Million to $1,285 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $894 Million.

Period: the year ended December 31, 2022
Revenue: $894 Million
Result: reported results

Exact text from the filing

Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALNYLAM PHARMACEUTICALS, INC. reported the quarter ended December 31, 2022 results: revenue $262 Million.

Period: the quarter ended December 31, 2022
Revenue: $262 Million
Result: reported results

Exact text from the filing

Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001157523-23-000344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.